EP1622607A1 - Angiotensin ii receptor blockers for preventing the development or progression of microvascular disease due to diabetes - Google Patents

Angiotensin ii receptor blockers for preventing the development or progression of microvascular disease due to diabetes

Info

Publication number
EP1622607A1
EP1622607A1 EP04730529A EP04730529A EP1622607A1 EP 1622607 A1 EP1622607 A1 EP 1622607A1 EP 04730529 A EP04730529 A EP 04730529A EP 04730529 A EP04730529 A EP 04730529A EP 1622607 A1 EP1622607 A1 EP 1622607A1
Authority
EP
European Patent Office
Prior art keywords
angiotensin
diabetes
progression
receptor blocker
development
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04730529A
Other languages
German (de)
French (fr)
Inventor
Sho-Ichi Yamagishi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim International GmbH
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH and Co KG, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim International GmbH
Publication of EP1622607A1 publication Critical patent/EP1622607A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Definitions

  • the present invention relates to the field of inhibitors of angiotensin II receptor blockers and particularly addresses their use in diabetes to prevent the development or progression of microvascular disease (i.e. disease involving small blood vessels) affecting eyes (diabetic retinopathy) and kidneys (diabetic nephropathy).
  • microvascular disease i.e. disease involving small blood vessels
  • kidneys diabetic nephropathy
  • Diabetes is a disorder in which the body is unable to metabolize carbohydrates (e.g., food starches, sugars, cellulose) properly.
  • carbohydrates e.g., food starches, sugars, cellulose
  • the disease is characterized by- excessive amounts of sugar in the blood (hyperglycemia) and urine, inadequate production and/or utilization of insulin, and by thirst, hunger, and loss of weight. Diabetes is affecting about 2% of the population. Of these 10-15% are insulin dependant (type 1) diabetics and the remainder non insulin dependant (type 2) diabetics.
  • Retinopathy is damage to the retina caused by microvascular changes. Diabetic retinopathy is a specific microvascular complication of both typel and type 2 diabetes. The prevalence of retinopathy is strongly linked to the duration of diabetes. After 20 years of diabetes nearly all patients with type 1 diabetes and over 60% of patients with type 2 diabetes have some degree of retinopathy. A diabetic is 25 times more likely to go blind than a person in the general population. Upton a fifth of newly diagnosed diabetics have been found to have some retinopathy. Additionally, retinopathy develops earlier and is more severe in diabetics with elevated systolic blood pressure levels.
  • Diabetic retinopathy is the most common cause of blindness in the working age population in many countries.
  • Proliferative retinopathy In the early phases of retinopathy, weakening of the small blood vessels in the retina produces bulges in the vessels (microaneurysms) and leakage of fluid (exudates) and blood (hemorrhages). Proliferative retinopathy, a later stage of the disease, involves the growth of fragile new blood vessels on the retina and into the vitreous, a jelly-like substance inside the eyeball. These vessels can rupture and release blood into the vitreous, which causes blurred vision or temporary blindness. The scar tissue that may subsequently develop can pull on the retina and cause retinal detachment, which may lead to permanent vision loss. Macular edema-swelling due to fluid accumulating around the macular, the part of the retina most crucial for fine vision, may also occur. If proliferative retinopathy is left untreated, about half of those who have it will become blind within five years, compared to just 5% of those who receive treatment.
  • the condition can be treated with laser photocoagulation, if it is detected early. Additionally, reduction in hyperglycemia at any time in the course of diabetes will result in a significant decrease in the long-term incidence and progression of retinopathy and in the development of visual loss.
  • the angiotensin converting enzyme (ACE) inhibitor lisinopril reduced the risk of . i ., progression of retinopathy by approximately 50%, and also significantly reduced the, risk of progression to proliferative retinopathy.
  • ACE angiotensin converting enzyme
  • Preventing the development or progression of the condition has the potential to save vision at a relatively low cost compared to the costs associated with a loss of vision.
  • Nephropathy is the deterioration of the kidneys. Diabetic nephropathy is a specific microvascular complication of both typel and type 2 diabetes. Type 1 diabetes is more likely to lead to the final stage of nephropathy called end-stage renal disease (ESRD). There are five stages of diabetic nephropathy, the fifth stage is ESRD. Progress from one stage to the next can take many years, with 23 years being the average length of time to reach stage five. Diabetes is the most common cause of ESRD accounting for more than 40 percent of cases in the US.
  • ESRD end-stage renal disease
  • angiotensin-ll-receptor blocker irbesartan is effective in protecting against the progression of nephropathy due to type II diabetes. Yet, preventing the development or progression of the condition has the potential/to save kidney function.
  • Angiotensin II plays a major role in pathophysiology, especially as the most potent blood pressure increasing agent in humans.
  • Angiotensin II receptor blockers particularly blockers of the type 1 receptor, are used for treating elevated blood pressure and congestive heart failure in a mammal.
  • angiotensin II receptor blockers also called angiotensin II antagonists
  • EP-A-253310 EP-A-323841 , EP-A-324377, EP-A-420237, EP-A-43983, EP-A-459136, EP-A-475206, EP-A-502314, EP-A-504888, EP-A-514198, WO 91/14679, WO 93/20816, US 4,355,040 and US 4,880,804.
  • angiotensin II receptor blockers are sartans such as candesartan, eprosartan, irbesartan, losartan, olmesartan, tasosartan, telmisartan or valsartan.
  • the ongoing Diabetic Retinopathy Candesartan Trials (DIRECT) program has been established to determine whether AT1 -receptor blockade with candesartan can prevent the incidence and progression of diabetic retinopathy.
  • This program involves normotensive or treated hypertensive individuals and will assess the potential of an AT1 -receptor blocker to protect against the pathological changes in the eye following diabetes. (Sj ⁇ lie and Chaturvedi, Journal of Human Hypertension (March 2002) 16 Suppl, pages 42-46).
  • angiotensin II receptor blockers the effect of angiotensin II receptor blockers on the development or progression of retinopathy is determined in a cell culture system avoiding extensive clinical trials.
  • the system allows to determine, whether or not a selected or potential angiotensin II inhibitor is effective in the prevention of the development or progression of retinopathy.
  • Pericytes regulate the growth of co-cultured endothelial cells and serve a pivotal role in the maintenance of microvascular: homeostasis. For instance they preserve the ability of co-cultured endothelial; cells .to produce prostacyclin y and to protect them against.lipid-peroxide-induced:.inj ⁇ ry..Pericyte loss and dysfunction. are characteristic histopathological hallmarks. observed. in the early phase ofdiabetic retinopathy.
  • the method according to the present invention allows to screen for angiotensin II receptor blockers, and in particular for angiotensin II receptor blockers which prevent the development or progression of diabetic retinopathy or nephropathy. It comprises
  • the cell culture system used is based on pericytes isolated from mammalian retina such as bovine retina.
  • the cells are maintained in commercially available cell culture media such as Dulbecco ' s Eagle ' s medium usually supplemented with fetal bovine serum.
  • reactive oxygen species comprises molecules like hydrogen peroxide, ions like the hypochlorite ion, radicals like the hydroxyl radical which is the most reactive of them all, and the superoxide anion which is both ion and radical.
  • An important aspect of the method is the finding that the intracellular generation of reactive oxygen species in pericytes increases in a dose-dependent manner after treating the cultured cells with angiotensin II.
  • VEGF vascular permeability factor
  • PDGF-B platelet - derived growth factor-B
  • Angiotensin II is a trigger of high blood pressure known as a major risk factor for diabetic retinopathy and nephropathy. Reactive oxygen species damage other molecules and, thus, the cell structures of which they are part. Generally cells use a variety of defenses against the harmful effects of reactive oxygen species including small molecules with antioxidative properties such as : alpha-tocopherol (vitamin E), uric acid, and.vitamin C or the two enzymes superoxide dismutase and catalase. Adding additional amounts of antioxidants like N-acetylcystein (NAC) during the treatment of pericytes with angiotensin II reverses the increase in the generation of reactive oxygen species induced by the presence of angiotensin II.
  • NAC N-acetylcystein
  • compounds which are devoid of antioxidative properties will prevent the development or progression of diabetic retinopathy or nephropathy, if they are capable of inhibiting in pericyte cell cultures the intracellular generation of reactive oxygen species induced by the presence of angiotensin II in the cell culture medium.
  • compounds can be screened by treating pericytes 1-48 hours, preferably 24 hours with or without angiotensin II in the presence or absence of such a compound. Following treatment the generation of reactive oxygen species is measured.
  • angiotensin II receptor blockers such as telmisartan were found to inhibit in pericyte cell cultures the increase in the generation of reactive oxygen species induced by angiotensin II, whereas treatment with the receptor blocker alone did not affect the generation of reactive oxygen species.
  • activation of angiotensin II receptor signaling in pericytes contributes to the pathogenesis of diabetic microvascular disease and antagonizing angiotensin II with compounds such as telmisartan prevent the development or progression of diseases such as diabetic retinopathy by attenuating pericyte loss and dysfunction.
  • the present invention teaches a method of 5 preventing the development or progression of microvascular disease due to diabetes such diabetic retinopathy or nephropathy comprising administering to an individual in need thereof a pharmaceutically effective amount of an angiotensin II receptor blocker.
  • the angiotensin II receptor blockers can be used for the production of a pharmaceutical composition to prevent the development or progression of 10 microvascular disease due to diabetes in an individual in need thereof.
  • angiotensin II receptor blockers are candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan or valsartan, but any receptor blocker can be used which is capable of inhibiting in pericyte cell cultures the: increase in the
  • the amount of receptor blocker used is dependent on the actual active ingredient and usually corresponds to the amount used to treat hypertension.
  • the active compounds can be administered orally, bucally, parenteraliy, by inhalation spray, rectally or topically, the oral administration being preferred. Parenteral administration
  • 25 may include subcutaneous, intravenous, intramuscular and intrasternal injections and infusion techniques.
  • the pharmaceutical composition for preventing the development or progression of diabetic retinopathy comprising a pharmaceutically effective amount of an 30 angiotensin II receptor blocker is primarily dependent on the way of administration. Dosage ranges include 0.5 to 500 mg/kg p.o., preferably 2 to 80 mg/kg p.o., and 3 mg/kg i.v.
  • the active compounds can be orally administered in a wide variety of different dosage forms, i.e. they may be formulated with various pharmaceutically acceptable inert carriers in the form of tablets, capsules, lozenges, troches, hard candies, powders, sprays, aqueous suspensions, elixirs, syrups, and the like.
  • Such carriers include solid diluents or fillers, sterile aqueous media and various non-toxic organic solvents, etc.
  • oral pharmaceutical formulations can be suitably sweetened and/or flavored by means of various agents of the type commonly employed for such purposes.
  • the compounds of this invention are present in such oral dosage forms at concentration levels ranging from about 0.5% to about 90% by weight of the total composition, in amounts which are sufficient to provide the desired unit dosages.
  • Other suitable dosage forms for the compounds of this - -invention include controlled release formulations and devices well known to hose •who practice in the art.
  • tablets containing various excipients su ⁇ h as sodium citrate, calcium carbonate and calcium phosphate may be employed along with various disintegrants such as starch and preferably potato or tapioca starch, alginic acid and certain complex silicate, together with binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia.
  • disintegrants such as starch and preferably potato or tapioca starch, alginic acid and certain complex silicate, together with binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia.
  • lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc or compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules; included lactose or milk sugar as well as high molecular weight polyethylene glycols.
  • the essential active ingredient therein may be combined with various sweetening or flavoring agents, coloring matter or dyes and, if so desired, emulsifying agents and/or water, ethanol, propylene glycol, glycerin and various like combinations thereof.
  • solutions of the compounds in sesame or peanut oil or in aqueous propylene glycol may be employed, as well as sterile aqueous solutions of the corresponding pharmaceutically acceptable salts.
  • aqueous solutions should be suitably buffered if necessary, and the liquid diluent rendered isotonic with sufficient saline or glucose.
  • sterile aqueous media employed are readily obtained by standard techniques well known to those skilled in the art.
  • distilled water is ordinarily used as the liquid diluent and the final preparation is passed through a suitable bacterial filter such as a sintered glass filter or a diatomaceousearth or unglazed porcelain filter.
  • suitable bacterial filter such as a sintered glass filter or a diatomaceousearth or unglazed porcelain filter.
  • Preferred filters of this type include the Berkefeld, the Chamberland and the Asbestos Disk-Metal Seitz filter, wherein the fluid is sucked into a sterile container with the aid of a suction pump. The necessary steps should be taken throughout the preparation of these injectable solutions to insure that the final products are obtained in a sterile condition.
  • the dosage form of the particular compound or compounds may include, by way of example, solutions, lotions, ointments, creams,, gels, suppositories, rate-limiting sustained release formulations and devices therefor.
  • dosage forms comprise the particular compound or compounds and may include ethanol, water, penetration enhancer and inert carriers such as gel-producing materials, mineral oil, emulsifying agents, benzyl alcohol and the like.
  • Angiotensin II receptor blockers may be administered in a daily dosage of 10 mg (or 0.143 mg/kg, based on a person of 70 kg) to 500 mg (7.143 mg/kg) orally and of about 20 mg (0.286 mg/kg) parenterally, preferably of 20 mg (0.286 mg/kg) to 100 mg (1.429 mg/kg) orally.
  • Particularly preferred is an oral daily dosage of 40 mg (0.571 mg/kg) to 80 mg (1.143 mg/kg) or specifically of about 80 mg (1.143 mg/kg).
  • angiotensin II receptor blockers are already on the market and can be used for administration, e.g. Approvel®, Atacand®, Blopress®, Cozaar®, Diovan®, Karvea®, Lortaan®, Lorzaar®, Losaprex®, Micardis®, Neo-Lotan® or Oscaar®, and Teveten®. Examples
  • Pericytes were isolated from bovine retina and maintained in Dulbecco ' s Eagle ' s medium supplemented with 20% of fetal bovine serum (FBS) as described in Yamagishi et al, Circulation 87:1969, 1993.
  • FBS fetal bovine serum
  • Angiotensin II treatment was carried out in medium containing 2% FBS. Pericytes were treated with or without 10 "7 or 10 "6 M angiotensin II in the presence or absence of 10 "7 M telmisartan for 24 hours. Then the intracellular formation of reactive oxygen species was detected as described in Yamagishi et al, A J Biol Chem 276:25096, 2001 by using the fluorescent probe CM-H 2 DCFDA (Molecular Probes Inc, Eugene, OR).
  • Angiotensin II increased intracellular generation of reactive oxygen species in a dose-dependent manner. 10 "6 M angiotensin II resulted in an increase of about 1.3 fold. Telmisartan was found to completely inhibit the angiotensin ll-induced increase in the generation of reactive oxygen species in pericytes, while telmisartan alone did not affect the generation.
  • Example 2 Measurement of [ 3 H]thymidine incorporation in pericytes
  • Pericytes were treated with or without 10 "7 M angiotensin in the presence or absence of 1mM N-acetylcystein (NAC) for 24 hours, and then [ 3 H]thymidine incorporation in cells was determined as described in Yamagishi et al, FEBS Lett 384:103, 1996.
  • Angiotensin II significantly inhibited DNA synthesis in pericytes.
  • NAC significantly prevented the angiotensin ll-induced decrease in DNA synthesis in pericytes.
  • Example 3 Quantitative reverse transcription PCR of VEGF m-RNA
  • RNAs were isolated from cells treated with or without 10 "7 M angiotensin II in the presence or absence of 10 "7 M telmisartan or 1 mM NAC for 4 hours, and analyzed by quantitative reverse transcription PCR (RT-PCR) as described in Yamagishi et al, Diabetologia 41 :1435, 1998.
  • RT-PCR quantitative reverse transcription PCR
  • VEGF mRNA level was about 1.5 fold higher than the basal level when exposed to 10 "7 M angiotensin II. Telmisartan and NAC were found to completely inhibit the angiotensin ll-induced up-regulation of VEGF mRNA levels in pericytes.
  • Partial cDNAs for bovine PDGF-B were cloned using primer sequences designed from the conserved amino acid sequences GELESL and NNRNVQ in human and sheep PDGF-B.
  • the upstream and downstream primers were 5'-GGCGAGCTGGAGAGCTT-3 ' and 5 ' -CTGCACGTTGCGGTTGT-3 ⁇ , respectively.
  • a 213-base pair RT-PCR product was amplified from 30 ng of bovine retinal pericyte poly(A) + RNA and cloned using the pGEM-T Easy Vector System according to the manufacturer's instructions (Promega, Madison, Wl, USA).
  • PCR products were sequenced by the chain termination method according to the manufacturer ' s instructions (DNA Sequencing Kit, Applied Biosystems, Foster, CA, USA).
  • the cloned bovine cDNA fragments showed strong sequence similarity with human and sheep PDGF-B. Nucleotide identities were 91% and 94%, amino acid identities 91% and 96% with human and sheep PDGF-B, respectively.
  • poly(A) + RNAs were isolated from cells treated with or without 10 "7 M angiotensin II in the presence or absence of 10 "7 M telmisartan or 1mM NAC for 4 hours, and analyzed by RT-PCR as. described in Yamagishi et al, Kidney Int 63:464, 2003.
  • the amounts of poly(A) + RNA templates (about 30ng) and cell cycle numbers for amplification (28 cycles for PDGF-B gene and 22 cycles for ⁇ -actin gene) were chosen in quantitative ranges were reactions proceeded linearly, which had been determined by plotting signal intensities as functions of the template amounts and cell cycle numbers as described in Yamagishi et al, J Biol Chem 277:20309, 2002. Sequences of primers for detecting bovine ⁇ -actin mRNAs were the same as described in Okamoto et al, FASEB J 16:1928, 2002.
  • PDGF-B has been implicated in vascular proliferative retinopathies, and hemizygous rhodopsin promoter/PDGF-B transgenic mice were shown to exhibit proliferation of vascular cells, glial cells and retinal pigment epithelial cells resulting in retinal detachment.
  • angiotensin II was found to significantly up- regulate PDGF-B mRNA levels in pericytes.
  • the PDGF-B mRNA level was about 5-fold higher than the basal level.
  • Telmisartan or NAC were found to significantly inhibit the angiotensin II induced up-regulation of PDGF mRNA levels.
  • angiotensin ll-type 1 receptor interaction is involved in the pathogenesis of retinal detachment in proliferative diabetic retinopathy through overexpression of PDGF-B, and that antagonizing angiotensin II action by angiotensin II receptor blockers delays or even prevents the progression of diabetic retinopathy by attenuating PDGF-B expression in vivo.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to the field of inhibitors of angiotensin II receptor blockers and particularly addresses their use in diabetes to prevent the development or progression of microvascular disease (i.e. disease involving small blood vessels) affecting eyes (diabetic retinopathy) and kidneys (diabetic nephropathy).

Description

ANGIOTENSIN II RECEPTOR BLOCKERS FOR PREVENTING THE DEVELOPMENT OR PROGRESSION OF MICROVASCULAR DISEASE DUE TO DIABETES
The present invention relates to the field of inhibitors of angiotensin II receptor blockers and particularly addresses their use in diabetes to prevent the development or progression of microvascular disease (i.e. disease involving small blood vessels) affecting eyes (diabetic retinopathy) and kidneys (diabetic nephropathy).
Diabetes is a disorder in which the body is unable to metabolize carbohydrates (e.g., food starches, sugars, cellulose) properly. The disease is characterized by- excessive amounts of sugar in the blood (hyperglycemia) and urine, inadequate production and/or utilization of insulin, and by thirst, hunger, and loss of weight. Diabetes is affecting about 2% of the population. Of these 10-15% are insulin dependant (type 1) diabetics and the remainder non insulin dependant (type 2) diabetics.
Retinopathy is damage to the retina caused by microvascular changes. Diabetic retinopathy is a specific microvascular complication of both typel and type 2 diabetes. The prevalence of retinopathy is strongly linked to the duration of diabetes. After 20 years of diabetes nearly all patients with type 1 diabetes and over 60% of patients with type 2 diabetes have some degree of retinopathy. A diabetic is 25 times more likely to go blind than a person in the general population. Upton a fifth of newly diagnosed diabetics have been found to have some retinopathy. Additionally, retinopathy develops earlier and is more severe in diabetics with elevated systolic blood pressure levels. On average, a careful eye examination reveals mild retinal abnormalities about seven years after the onset of diabetes, but the damage that threatens vision usually does not occur until much later. Diabetic retinopathy is the most common cause of blindness in the working age population in many countries.
In the early phases of retinopathy, weakening of the small blood vessels in the retina produces bulges in the vessels (microaneurysms) and leakage of fluid (exudates) and blood (hemorrhages). Proliferative retinopathy, a later stage of the disease, involves the growth of fragile new blood vessels on the retina and into the vitreous, a jelly-like substance inside the eyeball. These vessels can rupture and release blood into the vitreous, which causes blurred vision or temporary blindness. The scar tissue that may subsequently develop can pull on the retina and cause retinal detachment, which may lead to permanent vision loss. Macular edema-swelling due to fluid accumulating around the macular, the part of the retina most crucial for fine vision, may also occur. If proliferative retinopathy is left untreated, about half of those who have it will become blind within five years, compared to just 5% of those who receive treatment.
The condition can be treated with laser photocoagulation, if it is detected early. Additionally, reduction in hyperglycemia at any time in the course of diabetes will result in a significant decrease in the long-term incidence and progression of retinopathy and in the development of visual loss. In the EUCLID study, the angiotensin converting enzyme (ACE) inhibitor lisinopril reduced the risk of . i ., progression of retinopathy by approximately 50%, and also significantly reduced the, risk of progression to proliferative retinopathy. However, in the EUCLID Study.- -:■ '■: retinopathy was not a primary endpbint and the study was not sufficiently powered for eye-related outcomes. Preventing the development or progression of the condition has the potential to save vision at a relatively low cost compared to the costs associated with a loss of vision. Thus, it is an object of the present invention to provide further means which contribute to the prevention of the development or progression of diabetic retinopathy.
Nephropathy is the deterioration of the kidneys. Diabetic nephropathy is a specific microvascular complication of both typel and type 2 diabetes. Type 1 diabetes is more likely to lead to the final stage of nephropathy called end-stage renal disease (ESRD). There are five stages of diabetic nephropathy, the fifth stage is ESRD. Progress from one stage to the next can take many years, with 23 years being the average length of time to reach stage five. Diabetes is the most common cause of ESRD accounting for more than 40 percent of cases in the US.
Treatment for diabetic nephropathy attempts to manage and slow the progression of the disease. Aggressive blood pressure control is by far the most important factor in protecting kidney function. Angiotensin-con verting enzyme inhibitors are considered to provide the best protection for the kidneys. According to the RENAAL Study (Brenner et al, The New England Journal of Medicine 345:861-869, 2001) the angiotensin II receptor blocker losartan might offer similar protection, but concerns have been raised regarding to both the patient population as well as the outcome measures. Due to these methodological flaws and the incomplete data in the study, the question of the effectiveness and safety of this treatment in diabetic nephropathy remains unanswered (Fisr an et al, Cardiovascular Diabetology 1 :2, 2002). From the data of the similar IDNT study (Lewis et al, The New England Journal of Medicine 345:851-860, 2001) it has been concluded that the angiotensin-ll-receptor blocker irbesartan is effective in protecting against the progression of nephropathy due to type II diabetes. Yet, preventing the development or progression of the condition has the potential/to save kidney function Thus, it is another object of the present invention to provide further mearis whic contribute to the prevention of the , development or progression of diabetic: nephropathy.
Angiotensin II plays a major role in pathophysiology, especially as the most potent blood pressure increasing agent in humans. Angiotensin II receptor blockers, particularly blockers of the type 1 receptor, are used for treating elevated blood pressure and congestive heart failure in a mammal. Examples of angiotensin II receptor blockers (also called angiotensin II antagonists) are described in EP-A-253310 , EP-A-323841 , EP-A-324377, EP-A-420237, EP-A-43983, EP-A-459136, EP-A-475206, EP-A-502314, EP-A-504888, EP-A-514198, WO 91/14679, WO 93/20816, US 4,355,040 and US 4,880,804. Specific angiotensin II receptor blockers are sartans such as candesartan, eprosartan, irbesartan, losartan, olmesartan, tasosartan, telmisartan or valsartan.
The ongoing Diabetic Retinopathy Candesartan Trials (DIRECT) program has been established to determine whether AT1 -receptor blockade with candesartan can prevent the incidence and progression of diabetic retinopathy. This program involves normotensive or treated hypertensive individuals and will assess the potential of an AT1 -receptor blocker to protect against the pathological changes in the eye following diabetes. (Sjølie and Chaturvedi, Journal of Human Hypertension (August 2002) 16 Suppl, pages 42-46).
In the context of the present invention the effect of angiotensin II receptor blockers on the development or progression of retinopathy is determined in a cell culture system avoiding extensive clinical trials. The system allows to determine, whether or not a selected or potential angiotensin II inhibitor is effective in the prevention of the development or progression of retinopathy.
Vessels of the microvasculature are composed of only two types of cells, endothelial cells and pericytes. Pericytes regulate the growth of co-cultured endothelial cells and serve a pivotal role in the maintenance of microvascular: homeostasis. For instance they preserve the ability of co-cultured endothelial; cells .to produce prostacyclinyand to protect them against.lipid-peroxide-induced:.injύry..Pericyte loss and dysfunction. are characteristic histopathological hallmarks. observed. in the early phase ofdiabetic retinopathy.
The method according to the present invention allows to screen for angiotensin II receptor blockers, and in particular for angiotensin II receptor blockers which prevent the development or progression of diabetic retinopathy or nephropathy. It comprises
(a) treating pericyte tissue culture cells with or without angiotensin II in the presence or absence of a potential angiotensin II receptor blocker compound,
(b) measuring the amount of intracellularly generated reactive oxygen species, and
(c) identifying the compounds, which inhibit the intracellular generation of reactive oxygen species induced by the presence of angiotensin II in the culture medium.
The cell culture system used is based on pericytes isolated from mammalian retina such as bovine retina. The cells are maintained in commercially available cell culture media such as Dulbecco's Eagle's medium usually supplemented with fetal bovine serum. The term reactive oxygen species comprises molecules like hydrogen peroxide, ions like the hypochlorite ion, radicals like the hydroxyl radical which is the most reactive of them all, and the superoxide anion which is both ion and radical. An important aspect of the method is the finding that the intracellular generation of reactive oxygen species in pericytes increases in a dose-dependent manner after treating the cultured cells with angiotensin II. Simultaneously DNA synthesis as measured by the incorporation of [3H]thymidine in pericytes is decreased, whereas mRNAs for vascular permeability factor (VEGF), a specific mitogen to endothelial cells involved in the pathogenesis of proliferative diabetic retinopathy, and platelet - derived growth factor-B (PDGF-B), a potent mitogen and chemoattractant for microvascular endothelial cells and glial cells in the retina, are increased.
Angiotensin II is a trigger of high blood pressure known as a major risk factor for diabetic retinopathy and nephropathy. Reactive oxygen species damage other molecules and, thus, the cell structures of which they are part. Generally cells use a variety of defenses against the harmful effects of reactive oxygen species including small molecules with antioxidative properties such as:alpha-tocopherol (vitamin E), uric acid, and.vitamin C or the two enzymes superoxide dismutase and catalase. Adding additional amounts of antioxidants like N-acetylcystein (NAC) during the treatment of pericytes with angiotensin II reverses the increase in the generation of reactive oxygen species induced by the presence of angiotensin II.
Due to these findings, compounds which are devoid of antioxidative properties will prevent the development or progression of diabetic retinopathy or nephropathy, if they are capable of inhibiting in pericyte cell cultures the intracellular generation of reactive oxygen species induced by the presence of angiotensin II in the cell culture medium. Thus, compounds can be screened by treating pericytes 1-48 hours, preferably 24 hours with or without angiotensin II in the presence or absence of such a compound. Following treatment the generation of reactive oxygen species is measured. Using this screening method the angiotensin II receptor blockers such as telmisartan were found to inhibit in pericyte cell cultures the increase in the generation of reactive oxygen species induced by angiotensin II, whereas treatment with the receptor blocker alone did not affect the generation of reactive oxygen species. Thus, activation of angiotensin II receptor signaling in pericytes contributes to the pathogenesis of diabetic microvascular disease and antagonizing angiotensin II with compounds such as telmisartan prevent the development or progression of diseases such as diabetic retinopathy by attenuating pericyte loss and dysfunction.
As a consequence of these results the present invention teaches a method of 5 preventing the development or progression of microvascular disease due to diabetes such diabetic retinopathy or nephropathy comprising administering to an individual in need thereof a pharmaceutically effective amount of an angiotensin II receptor blocker. The angiotensin II receptor blockers can be used for the production of a pharmaceutical composition to prevent the development or progression of 10 microvascular disease due to diabetes in an individual in need thereof.
Preferred examples of angiotensin II receptor blockers are candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan or valsartan, but any receptor blocker can be used which is capable of inhibiting in pericyte cell cultures the: increase in the
15. generation of reactive oxygen species induced by angiotensin H Individuals considered to be in need of such a treatment are affected by one or more risk factors of diabetic retinopathy. Examples of such risk factors are diabetes, elevated blood glucose level, proteinuria, elevated blood urea nitrogen, elevated blood creatinine, microalbuminuria or systemic hypertension.
20
The amount of receptor blocker used is dependent on the actual active ingredient and usually corresponds to the amount used to treat hypertension. The active compounds can be administered orally, bucally, parenteraliy, by inhalation spray, rectally or topically, the oral administration being preferred. Parenteral administration
25 may include subcutaneous, intravenous, intramuscular and intrasternal injections and infusion techniques.
The pharmaceutical composition for preventing the development or progression of diabetic retinopathy comprising a pharmaceutically effective amount of an 30 angiotensin II receptor blocker is primarily dependent on the way of administration. Dosage ranges include 0.5 to 500 mg/kg p.o., preferably 2 to 80 mg/kg p.o., and 3 mg/kg i.v. The active compounds can be orally administered in a wide variety of different dosage forms, i.e. they may be formulated with various pharmaceutically acceptable inert carriers in the form of tablets, capsules, lozenges, troches, hard candies, powders, sprays, aqueous suspensions, elixirs, syrups, and the like. Such carriers include solid diluents or fillers, sterile aqueous media and various non-toxic organic solvents, etc. Moreover, such oral pharmaceutical formulations can be suitably sweetened and/or flavored by means of various agents of the type commonly employed for such purposes. In general, the compounds of this invention are present in such oral dosage forms at concentration levels ranging from about 0.5% to about 90% by weight of the total composition, in amounts which are sufficient to provide the desired unit dosages. Other suitable dosage forms for the compounds of this - -invention include controlled release formulations and devices well known to hose •who practice in the art.
For purposes of oral administration, tablets containing various excipients suδh as sodium citrate, calcium carbonate and calcium phosphate may be employed along with various disintegrants such as starch and preferably potato or tapioca starch, alginic acid and certain complex silicate, together with binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc or compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules; included lactose or milk sugar as well as high molecular weight polyethylene glycols. When aqueous suspensions and/or elixirs are desired for oral administration, the essential active ingredient therein may be combined with various sweetening or flavoring agents, coloring matter or dyes and, if so desired, emulsifying agents and/or water, ethanol, propylene glycol, glycerin and various like combinations thereof.
For purposes of parenteral administration, solutions of the compounds in sesame or peanut oil or in aqueous propylene glycol may be employed, as well as sterile aqueous solutions of the corresponding pharmaceutically acceptable salts. Such aqueous solutions should be suitably buffered if necessary, and the liquid diluent rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular and sub-cutaneous injection purposes. In this connection, the sterile aqueous media employed are readily obtained by standard techniques well known to those skilled in the art. For instance, distilled water is ordinarily used as the liquid diluent and the final preparation is passed through a suitable bacterial filter such as a sintered glass filter or a diatomaceousearth or unglazed porcelain filter. Preferred filters of this type include the Berkefeld, the Chamberland and the Asbestos Disk-Metal Seitz filter, wherein the fluid is sucked into a sterile container with the aid of a suction pump. The necessary steps should be taken throughout the preparation of these injectable solutions to insure that the final products are obtained in a sterile condition. For purposes of transdermal administration, the dosage form of the particular compound or compounds may include, by way of example, solutions, lotions, ointments, creams,, gels, suppositories, rate-limiting sustained release formulations and devices therefor. Such dosage forms comprise the particular compound or compounds and may include ethanol, water, penetration enhancer and inert carriers such as gel-producing materials, mineral oil, emulsifying agents, benzyl alcohol and the like.
Angiotensin II receptor blockers may be administered in a daily dosage of 10 mg (or 0.143 mg/kg, based on a person of 70 kg) to 500 mg (7.143 mg/kg) orally and of about 20 mg (0.286 mg/kg) parenterally, preferably of 20 mg (0.286 mg/kg) to 100 mg (1.429 mg/kg) orally. Particularly preferred is an oral daily dosage of 40 mg (0.571 mg/kg) to 80 mg (1.143 mg/kg) or specifically of about 80 mg (1.143 mg/kg).
Several angiotensin II receptor blockers are already on the market and can be used for administration, e.g. Approvel®, Atacand®, Blopress®, Cozaar®, Diovan®, Karvea®, Lortaan®, Lorzaar®, Losaprex®, Micardis®, Neo-Lotan® or Oscaar®, and Teveten®. Examples
All values were presented as means ± standard errors (SE). Statistical significance was evaluated using Student's t test for paired comparison; P<0.05 was considered significant.
Example 1 - Measurement of reactive oxygen species in pericytes
Pericytes were isolated from bovine retina and maintained in Dulbecco's Eagle's medium supplemented with 20% of fetal bovine serum (FBS) as described in Yamagishi et al, Circulation 87:1969, 1993.
Angiotensin II treatment was carried out in medium containing 2% FBS. Pericytes were treated with or without 10"7 or 10"6 M angiotensin II in the presence or absence of 10"7 M telmisartan for 24 hours. Then the intracellular formation of reactive oxygen species was detected as described in Yamagishi et al, A J Biol Chem 276:25096, 2001 by using the fluorescent probe CM-H2DCFDA (Molecular Probes Inc, Eugene, OR).
Angiotensin II increased intracellular generation of reactive oxygen species in a dose-dependent manner. 10"6 M angiotensin II resulted in an increase of about 1.3 fold. Telmisartan was found to completely inhibit the angiotensin ll-induced increase in the generation of reactive oxygen species in pericytes, while telmisartan alone did not affect the generation.
Example 2 - Measurement of [3H]thymidine incorporation in pericytes Pericytes were treated with or without 10"7 M angiotensin in the presence or absence of 1mM N-acetylcystein (NAC) for 24 hours, and then [3H]thymidine incorporation in cells was determined as described in Yamagishi et al, FEBS Lett 384:103, 1996. Angiotensin II significantly inhibited DNA synthesis in pericytes. NAC significantly prevented the angiotensin ll-induced decrease in DNA synthesis in pericytes. Example 3 - Quantitative reverse transcription PCR of VEGF m-RNA
Sequences and primers for detecting VEGF and β-actin mRNAs are described in Yamagishi et al, J Biol Chem 272:8723, 1997.
Poly(A)+ RNAs were isolated from cells treated with or without 10"7 M angiotensin II in the presence or absence of 10"7 M telmisartan or 1 mM NAC for 4 hours, and analyzed by quantitative reverse transcription PCR (RT-PCR) as described in Yamagishi et al, Diabetologia 41 :1435, 1998. The amounts of poly(A)+ RNA templates (about 30ng) and cell cycle numbers for amplification (28 cycles for VEGF gene and 22 cycles for β-actin gene) were chosen in quantitative ranges were reactions proceeded linearly, which had been determined by plotting signal intensities as functions of the template amounts and cell cycle numbers as described in Yamagishi et al, J Biol Chem 277:20309, 2002.
It has been reported that there exist five alternatively spliced products from the single VEGF gene. They are designated as VEGF121, VEGF145, VEGF165 VEGFι8g, and VEGF2o6- Since Northern blot analysis can not clearly discriminate these five mRNA products, we employed a more sensitive semi-quantitative RT-PCR technique as described in Okamoto et al, FASEB J 16:1928, 2002. In these experiments, cDNA products of 486 and 618 base pairs length are amplified from mRNAs for VEGF12ι and VEGF165, respectively. Angiotensin II significantly up-regulated these secretory forms of VEGF mRNA levels in pericytes. The VEGF mRNA level was about 1.5 fold higher than the basal level when exposed to 10"7 M angiotensin II. Telmisartan and NAC were found to completely inhibit the angiotensin ll-induced up-regulation of VEGF mRNA levels in pericytes.
Example 4 - Molecular cloning of bovine PDGF-B partial cDNAs
Partial cDNAs for bovine PDGF-B were cloned using primer sequences designed from the conserved amino acid sequences GELESL and NNRNVQ in human and sheep PDGF-B. The upstream and downstream primers were 5'-GGCGAGCTGGAGAGCTT-3' and 5'-CTGCACGTTGCGGTTGT-3^ , respectively. A 213-base pair RT-PCR product was amplified from 30 ng of bovine retinal pericyte poly(A)+ RNA and cloned using the pGEM-T Easy Vector System according to the manufacturer's instructions (Promega, Madison, Wl, USA). Cloned PCR products were sequenced by the chain termination method according to the manufacturer's instructions (DNA Sequencing Kit, Applied Biosystems, Foster, CA, USA). The cloned bovine cDNA fragments showed strong sequence similarity with human and sheep PDGF-B. Nucleotide identities were 91% and 94%, amino acid identities 91% and 96% with human and sheep PDGF-B, respectively.
Example 5 - Quantitative reverse transcription PCR of PDGF-B m-RNA
To investigate the effects of angiotensin II on PDGF-B gene expression in cultured retinal pericytes, poly(A)+ RNAs were isolated from cells treated with or without 10"7 M angiotensin II in the presence or absence of 10"7 M telmisartan or 1mM NAC for 4 hours, and analyzed by RT-PCR as. described in Yamagishi et al, Kidney Int 63:464, 2003. The amounts of poly(A)+ RNA templates (about 30ng) and cell cycle numbers for amplification (28 cycles for PDGF-B gene and 22 cycles for β-actin gene) were chosen in quantitative ranges were reactions proceeded linearly, which had been determined by plotting signal intensities as functions of the template amounts and cell cycle numbers as described in Yamagishi et al, J Biol Chem 277:20309, 2002. Sequences of primers for detecting bovine β-actin mRNAs were the same as described in Okamoto et al, FASEB J 16:1928, 2002. PDGF-B has been implicated in vascular proliferative retinopathies, and hemizygous rhodopsin promoter/PDGF-B transgenic mice were shown to exhibit proliferation of vascular cells, glial cells and retinal pigment epithelial cells resulting in retinal detachment. In the present experiment angiotensin II was found to significantly up- regulate PDGF-B mRNA levels in pericytes. When exposed to 10"7 M angiotensin II the PDGF-B mRNA level was about 5-fold higher than the basal level. Telmisartan or NAC were found to significantly inhibit the angiotensin II induced up-regulation of PDGF mRNA levels. From this it is concluded that angiotensin ll-type 1 receptor interaction is involved in the pathogenesis of retinal detachment in proliferative diabetic retinopathy through overexpression of PDGF-B, and that antagonizing angiotensin II action by angiotensin II receptor blockers delays or even prevents the progression of diabetic retinopathy by attenuating PDGF-B expression in vivo.

Claims

Claims
1. A method of preventing the development or progression of microvascular disease due to diabetes comprising administering to an individual in need thereof a pharmaceutically effective amount of an angiotensin II receptor blocker.
2. The method of claim 1 , wherein the angiotensin II receptor blocker is a receptor blocker which in pericyte cell culture inhibits the intracellular generation of reactive oxygen species induced by the presence of angiotensin II in the culture medium.
3. The method of claim 2, wherein the angiotensin II receptor blocker is selected from candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan or valsartan.
4. The method of claim 1 preventing the development or progression of diabetic retinopathy.
5. The method of claim 1 , wherein the individual is affected by one or more of the risk factors diabetes, elevated blood glucose level, proteinuria, elevated blood urea nitrogen, elevated blood creatinine, microalbuminuria or systemic hypertension.
6. A method to screen for angiotensin II receptor blockers which prevent the development or progression of microvascular disease due to diabetes, comprising
(a) treating pericyte tissue culture cells with or without angiotensin II in the presence or absence of a potential angiotensin II receptor blocker compound,
(b) measuring the amount of intracellularly generated reactive oxygen species, and (c) identifying the compounds, which inhibit the intracellular generation of reactive oxygen species induced by the presence of angiotensin II in the culture medium.
7. A pharmaceutical composition for preventing the development or progression of microvascular disease due to diabetes such as diabetic retinopathy comprising a pharmaceutically effective amount of an angiotensin II receptor blocker.
8. Use of an angiotensin II receptor blocker for the production of a pharmaceutical composition to prevent the development or progression of microvascular disease due to diabetes such as diabetic retinopathy in an individual in need thereof.
9. The use according to claim 8, wherein the angiotensin II receptor blocker is a receptor blocker which in pericyte cell culture inhibits the intracellular generation of reactive oxygen species induced by the presence of angiotensin II in the culture medium.
10. The use according to claim 9, wherein the inhibitor of the angiotensin II receptor blocker is selected from candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan or valsartan.
11. The use of claim 8, wherein the individual is affected by one or more of the risk factors diabetes, elevated blood glucose level, proteinuria, elevated blood urea nitrogen, elevated blood creatinine, microalbuminuria or systemic hypertension.
EP04730529A 2003-05-02 2004-04-30 Angiotensin ii receptor blockers for preventing the development or progression of microvascular disease due to diabetes Withdrawn EP1622607A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10319592A DE10319592A1 (en) 2003-05-02 2003-05-02 Treatment of diabetic retinopathy with angiotensin II receptor blockers
PCT/EP2004/004616 WO2004096211A1 (en) 2003-05-02 2004-04-30 Angiotensin ii receptor blockers for preventing the development or progression of microvascular disease due to diabetes

Publications (1)

Publication Number Publication Date
EP1622607A1 true EP1622607A1 (en) 2006-02-08

Family

ID=33305091

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04730529A Withdrawn EP1622607A1 (en) 2003-05-02 2004-04-30 Angiotensin ii receptor blockers for preventing the development or progression of microvascular disease due to diabetes

Country Status (12)

Country Link
EP (1) EP1622607A1 (en)
JP (1) JP2006525269A (en)
KR (1) KR20060009288A (en)
CN (1) CN1784225A (en)
AU (1) AU2004233597A1 (en)
BR (1) BRPI0409853A (en)
CA (1) CA2524248A1 (en)
DE (1) DE10319592A1 (en)
MX (1) MXPA05011760A (en)
RU (1) RU2005137361A (en)
WO (1) WO2004096211A1 (en)
ZA (1) ZA200508263B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7812770B2 (en) 2006-08-29 2010-10-12 Research In Motion Limited Mobile wireless communications device including an electrically conductive, electrically floating element and related methods

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009087900A1 (en) * 2008-01-11 2009-07-16 Daiichi Sankyo Company, Limited Pharmaceutical agent for prevention or treatment of diseases accompanied by intraocular vascular hyperpermeability
JP5860210B2 (en) * 2010-12-07 2016-02-16 株式会社オフテクス Composition for promoting lacrimal secretion containing at least one of telmisartan and losartan, an angiotensin II receptor antagonist, and a preparation for oral administration containing lacrimal secretion containing the composition
KR102233673B1 (en) * 2016-01-27 2021-03-30 보령제약 주식회사 Pharmaceutical composition for preventing or treating diabetic nephropathy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004096215A1 (en) * 2003-04-30 2004-11-11 Boehringer Ingelheim International Gmbh Pharmaceutical formulation of the sodium salt of telmisartan

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI9210098B (en) * 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoles, drugs with this compounds, and process for their preparation
CA2420055C (en) * 2000-08-25 2010-06-01 Takeda Chemical Industries, Ltd. Fibrinogen-lowering agent
US20020091082A1 (en) * 2000-09-13 2002-07-11 Aiello Lloyd P. Methods of modulating symptoms of hypertension
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004096215A1 (en) * 2003-04-30 2004-11-11 Boehringer Ingelheim International Gmbh Pharmaceutical formulation of the sodium salt of telmisartan

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2004096211A1 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7812770B2 (en) 2006-08-29 2010-10-12 Research In Motion Limited Mobile wireless communications device including an electrically conductive, electrically floating element and related methods
US8068061B2 (en) 2006-08-29 2011-11-29 Research In Motion Limited Mobile wireless communications device including an electrically conductive, electrically floating element and related methods
US8274438B2 (en) 2006-08-29 2012-09-25 Research In Motion Limited Mobile wireless communications device including an electrically conductive, electrically floating element and related methods
US8487819B2 (en) 2006-08-29 2013-07-16 Research In Motion Limited Mobile wireless communications device including an electrically conductive, electrically floating element and related methods

Also Published As

Publication number Publication date
BRPI0409853A (en) 2006-05-16
MXPA05011760A (en) 2006-01-26
CN1784225A (en) 2006-06-07
DE10319592A1 (en) 2004-11-18
AU2004233597A1 (en) 2004-11-11
CA2524248A1 (en) 2004-11-11
KR20060009288A (en) 2006-01-31
ZA200508263B (en) 2007-02-28
JP2006525269A (en) 2006-11-09
RU2005137361A (en) 2006-07-27
WO2004096211A1 (en) 2004-11-11

Similar Documents

Publication Publication Date Title
Villapol et al. Neurorestoration after traumatic brain injury through angiotensin II receptor blockage
Taira et al. Spironolactone exhibits direct renoprotective effects and inhibits renal renin–angiotensin–aldosterone system in diabetic rats
Tanaka et al. The potential for renoprotection with incretin-based drugs
Lei et al. Salidroside protects pulmonary artery endothelial cells against hypoxia-induced apoptosis via the AhR/NF-κB and Nrf2/HO-1 pathways
Li et al. ZLN005 protects cardiomyocytes against high glucose-induced cytotoxicity by promoting SIRT1 expression and autophagy
Osman et al. Pioglitazone, a PPARγ agonist, attenuates PDGF-induced vascular smooth muscle cell proliferation through AMPK-dependent and AMPK-independent inhibition of mTOR/p70S6K and ERK signaling
Min et al. Renal complications of diabetes
Nagisa et al. The angiotensin II receptor antagonist candesartan cilexetil (TCV-116) ameliorates retinal disorders in rats
Kim et al. Aminoguanidine protects against apoptosis of retinal ganglion cells in Zucker diabetic fatty rats
KR20090080954A (en) Angiotensin II Receptor Antagonists for Treating Systemic Diseases in Cats
Kanda et al. (Pro) renin receptor: Involvement in diabetic retinopathy and development of molecular targeted therapy
Ren et al. Up-regulation thioredoxin inhibits advanced glycation end products-induced neurodegeneration
CA2784297A1 (en) Compositions and methods related to mirna in diabetic conditions
Zhang et al. Long non-coding RNA KCNQ1OT1 promotes hydrogen peroxide-induced lens epithelial cell apoptosis and oxidative stress by regulating miR-223-3p/BCL2L2 axis
Zhou et al. Renoprotective effect of atorvastatin on STZ-diabetic rats through attenuating kidney-associated dysmetabolism
Hou et al. Azilsartan ameliorates ventricular hypertrophy in rats suffering from pressure overload-induced cardiac hypertrophy by activating the Keap1–Nrf2 signalling pathway
Gong et al. Inhibiting autophagy by miR-19a-3p/PTEN regulation protected retinal pigment epithelial cells from hyperglycemic damage
Fu et al. Metformin protects human lens epithelial cells from high glucose-induced senescence and autophagy inhibition by upregulating SIRT1
Zhan et al. Telmisartan mitigates high-glucose-induced injury in renal glomerular endothelial cells (rGECs) and albuminuria in diabetes mice
EP1622607A1 (en) Angiotensin ii receptor blockers for preventing the development or progression of microvascular disease due to diabetes
US20050038093A1 (en) Treating diabetic retinopathy with angiotensin II receptor blockers
Nagata et al. Competitive inhibition of SGLT2 by tofogliflozin or phlorizin induces urinary glucose excretion through extending splay in cynomolgus monkeys
Ono et al. Gene expression changes in the retina after systemic administration of aldosterone
Matsui et al. Irbesartan inhibits advanced glycation end product (AGE)-induced up-regulation of vascular cell adhesion molecule-1 (VCAM-1) mRNA levels in glomerular endothelial cells
Guo et al. Mitofusin 2 inhibits high glucose-induced apoptosis of human lens epithelial cells via modulating mitochondrial function and autophagy

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20051202

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: LT LV

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG

Owner name: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

RAX Requested extension states of the european patent have changed

Extension state: LV

Payment date: 20051202

Extension state: LT

Payment date: 20051202

17Q First examination report despatched

Effective date: 20061123

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20091103